TIAA CREF Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-90,243
| Closed | -$334K | – | 3096 |
|
|
2017
Q4 | $334K | Sell |
90,243
-5,863
| -6% | -$24K | ﹤0.01% | 2916 |
|
|
2017
Q3 | $393K | Buy |
96,106
+2,578
| +3% | +$9.86K | ﹤0.01% | 2933 |
|
|
2017
Q2 | $347K | Buy |
+93,528
| New | +$371K | ﹤0.01% | 3000 |
|
|
2016
Q2 | – | Sell |
-52,700
| Closed | -$402K | – | 3233 |
|
|
2016
Q1 | $402K | Hold |
52,700
| – | – | ﹤0.01% | 2845 |
|
|
2015
Q4 | $702K | Buy |
52,700
+8,349
| +19% | +$144K | ﹤0.01% | 2774 |
|
|
2015
Q3 | $729K | Sell |
44,351
-6,497
| -13% | -$133K | ﹤0.01% | 2748 |
|
|
2015
Q2 | $1.14M | Buy |
50,848
+4,736
| +10% | +$74.9K | ﹤0.01% | 2630 |
|
|
2015
Q1 | $451K | Hold |
46,112
| – | – | ﹤0.01% | 2952 |
|
|
2014
Q4 | $526K | Buy |
46,112
+3,366
| +8% | +$36.5K | ﹤0.01% | 2950 |
|
|
2014
Q3 | $492K | Sell |
42,746
-1,439
| -3% | -$22K | ﹤0.01% | 2976 |
|
|
2014
Q2 | $859K | Buy |
+44,185
| New | +$780K | ﹤0.01% | 2807 |
|
|
2013
Q3 | – | Sell |
-931
| Closed | -$9K | – | 3132 |
|
|
2013
Q2 | $9K | Buy |
+931
| New | +$12K | ﹤0.01% | 3092 |
|
TIAA CREF Investment Management's CASC Position: Q1 2018 in Review
TIAA CREF Investment Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 90,243 shares — an estimated $334K sold.
TIAA CREF Investment Management first reported a position in CASC in Q2 2013 and held it in 12 quarters. The position peaked at $1.14M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- TIAA CREF Investment Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- TIAA CREF Investment Management sold 90,243 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $334K.
- TIAA CREF Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
- TIAA CREF Investment Management's Cascadian Therapeutics, Inc. position peaked at $1.14M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.